LEXINGTON, Mass. (AP) _ Concert Pharmaceuticals Inc. (CNCE) on Thursday reported a third-quarter loss of $17.4 million, after reporting a profit in the same period a year earlier.
On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 74 cents.
The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 62 cents per share.
The biopharmaceutical company posted revenue of $11,000 in the period.
Concert shares have dropped 42 percent since the beginning of the year. The stock has decreased 12 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CNCE at https://www.zacks.com/ap/CNCE